Model organisms: The mighty mouse: genetically engineered mouse models in cancer drug development
By N. Sharpless, R. DePinho. Nature reviews. Drug discovery, 2006
627 citations recorded by the source corpus.
Subfields: Biotechnology, Cancer Research, Oncology
View Paper: https://www.semanticscholar.org/paper/360e51e999184601ba60a8b5232550752a90a221
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biotechnology
In Cancer Research
In Oncology
Citations in the corpus
- Mechanisms and functions of cellular senescence. (2018, neutral): “Persistent stress or additional signals can activate p16 INK4a , an inhibitor of CDK4 and CDK6, contributing to a long-lasting arrest (40).”
- Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021, background): “This crucial role is evident from the fact that loss of the p16INK4A gene or inherited mutations within it have been frequently related to several human cancers particularly malignant melanoma (Gil and Peters, 2006; Kim and Sharpless, 2006; Li et al., 2011).”
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs (2008, background): “In addition, xenografts in immunodeficient mice do not sufficiently mimic the tumor–host interactions of real breast cancers in women (10).”
- Paul Ehrlich's magic bullet concept: 100 years of progress (2008, neutral): “Appropriate animal tumour models, (as originally studied by Ehrlich and Apolant), in vitro models for mechanism-based toxicity and molecularly defined targeted disruption of cancer genes in animal models are important tools for a better prediction of side-effect”
- Illuminating the metastatic process (2007, neutral): “Imaging for longer periods and analysis of mouse models that more closely recapitulate human cancer should help to address these issue”
- Maximizing mouse cancer models (2007, neutral): “There are many considerations for conducting such studies properly, including an appropriate physical infrastructure and trained personnel, a stable financial arrangement that is challenging to attain in most academic centres, and an engaged legal affairs office to address the significant intellectu”
- Guidelines for the welfare and use of animals in cancer research (2010, background): “A key question that continues to be debated is whether human cancer xenografts or murine transgenic models best reflect the human disease in terms of biology and predictions of efficacy of therapeutic agents (Becher et al, 2006; Dennis, 2006; Garber, 2006; Sausville et al, 2006; Sharpless and DePinh”
- Imaging in the era of molecular oncology (2008, positive): “…valuable in genetically engineered mouse models in which the activation of oncogenes and/or tumour-suppressor genes is under temporal and tissue-specific control, because the reporters enable not only oncogenic transformation to be studied but also drug action, toxicity and resistance28,29.”
- Modelling breast cancer: one size does not fit all (2007, neutral): “However, it is important to recognize that, in general, xenograft models have limited use in predicting whether anticancer agents will be effective in treating human cance”
- Malignant astrocytic glioma: genetics, biology, and paths to treatment. (2007, positive): “…GEM models of glioma should enable the identification of tumor maintenance genes and the testing of agents targeting such mission critical lesions, thereby identifying key targets, the best agent, and the right patient population (i.e., genotype) (for review, see Sharpless and Depinho 2006).”